GlassScriptPhysician profile
Matthew W Meier
NPI 1578574372
$10,797.57
in general payments reported to CMS, 2019-2025
46 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $1,382 · 2021: $1,759 · 2022: $1,642 · 2023: $1,986 · 2024: $1,434 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,598.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,517.70 | 2021-2025 | |
| Novo Nordisk INC | $1,435.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,278.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $510.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $483.59 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $451.29 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Vanda Pharmaceuticals INC. | $414.36 | 2024-2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $408.96 | 2024-2025 | Voquezna |
| Nevro Corp. | $332.52 | 2022-2023 | Senza |
| Amgen INC. | $322.70 | 2019-2023 | Repatha, Otezla |
| Antares Pharma, INC. | $317.75 | 2019-2025 | Xyosted |
| Eisai INC. | $241.85 | 2020-2021 | |
| Corcept Therapeutics | $233.96 | 2023 | Korlym |
| Sumitomo Pharma America, INC. | $221.29 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $194.45 | 2019-2025 | Zoryve |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.